Price Alert

Tiziana Life Sciences Ltd (TLSA)

NASDAQ: TLSA · Real-Time Price · USD

1.90

-0.07 (-3.55%)

At close: Aug 18, 2025, 3:59 PM

1.95

2.85%

After-hours: Aug 18, 2025, 06:18 PM EDT

-3.55% (1D)

Bid	1.85
Market Cap	105.61M
Revenue (ttm)	n/a
Net Income (ttm)	-10.88M
EPS (ttm)	-0.11
PE Ratio (ttm)	-17.23
Forward PE	-13.75
Analyst	n/a

Ask	1.95
Volume	765,502
Avg. Volume (20D)	339,343
Open	1.94
Previous Close	1.97
Day's Range	1.83 - 1.99
52-Week Range	0.63 - 2.60
Beta	0.24

About TLSA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TLSA

Website n/a

Full Company Profile

Why Price Moved

2 months ago

+9.15%

Tiziana Life Sciences shares are trading higher af... Unlock content with Pro Subscription

2 months ago

+15.33%

Tiziana Life Sciences shares are trading higher after the company highlighted clinical progress for its intranasal alzheimer's therapy.

News

3 days ago · proactiveinvestors.com

Tiziana Life Sciences doses first MSA patient in new trial – ICYMI

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about the company's latest milestone: dosing the first patient in its Phase 2a clinical trial targeting multiple system at...

4 days ago · proactiveinvestors.com

Tiziana Life Sciences doses first patient in Phase 2a MSA trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has enrolled and dosed the first participant in its Phase 2a clinical trial evaluating intranasal foralumab in patients with Multiple System A...

1 week ago · proactiveinvestors.com

Tiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDA

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the US Food & Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its Phase 2a clinical trial of intranasal...

4 weeks ago · proactiveinvestors.com

Tiziana Life Sciences reports encouraging results from nasal Alzheimer's treatment

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said that its experimental nasal treatment for Alzheimer's disease showed promising results in a patient, helping reduce brain inflammation and possibly aiding ...

2 months ago · seekingalpha.com

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

Tiziana is developing foralumab, a fully human anti-CD3 monoclonal antibody, for non-active secondary progressive multiple sclerosis patients, with key data expected in 2026. A phase 2 trial of foralu...

2 months ago · proactiveinvestors.com

Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has initiated patient dosing at the Weill Cornell Medicine Multiple Sclerosis Center in New York City as part of its ongoing Phase 2 clinical ...